

30-04-2020

Information for healthcare professionals

National Institute for Health and Care Excellence (NICE) (Reino Unido) – COVID-19 Rapid guidelines and evidence summaries

Cuando comenzó la pandemia de COVID-19, el *National Institute for Health and Care Excellence* (NICE) de Reino Unido inició la publicación de una serie de *Rapid guidelines and evidence summaries*.

Incluimos en este apartado los enlaces a estas *guidelines*.
Enlaces comprobados el 27 de abril de 2020

NICE - COVID-19 Rapid guidelines and evidence summaries

Pueden consultarse todos los documentos publicados en el siguiente enlace:

<https://www.nice.org.uk/guidance/conditions-and-diseases/infections/covid19/products?Status=Published>

Esta página va actualizándose a medida que se crean nuevos documentos o se actualizan algunos de los ya existentes.

1. [COVID-19 rapid guideline: critical care in adults \(NG159\)](#)

Product type: Guidance

Programme: NICE guideline

Last updated: 24 April 2020

Published date: 20 March 2020

2. [COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders \(NG167\)](#)

Product type: Guidance

Programme: NICE guideline

Last updated: 24 April 2020

Published date: 3 April 2020

3. [COVID-19 rapid guideline: acute myocardial injury \(NG171\)](#)

Product type: Guidance

Programme: NICE guideline

Published date: 23 April 2020

4. [COVID-19 rapid guideline: gastrointestinal and liver conditions treated with drugs affecting the immune response \(NG172\)](#)

Product type: Guidance

Programme: NICE guideline

Published date: 23 April 2020

5. [COVID-19 rapid guideline: managing suspected or confirmed pneumonia in adults in the community \(NG165\)](#)

Product type: Guidance

Programme: NICE guideline

Last updated: 23 April 2020

Published date: 3 April 2020

6. [COVID-19 rapid guideline: managing symptoms \(including at the end of life\) in the community \(NG163\)](#)

Product type: Guidance

Programme: NICE guideline

Last updated: 22 April 2020

Published date: 3 April 2020

7. [COVID-19 rapid guideline: cystic fibrosis \(NG170\)](#)

Product type: Guidance

Programme: NICE guideline

Published date: 9 April 2020

8. [COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response \(NG169\)](#)

Product type: Guidance

Programme: NICE guideline

Published date: 9 April 2020

9. [COVID-19 rapid guideline: community-based care of patients with chronic obstructive pulmonary disease \(COPD\) \(NG168\)](#)

Product type: Guidance

Programme: NICE guideline

Published date: 9 April 2020

10. [COVID-19 rapid guideline: delivery of systemic anticancer treatments \(NG161\)](#)

Product type: Guidance

Programme: NICE guideline

Last updated: 9 April 2020

Published date: 20 March 2020

11. [COVID-19 rapid guideline: severe asthma \(NG166\)](#)

Product type: Guidance

Programme: NICE guideline

Published date: 3 April 2020

12. [COVID-19 rapid guideline: haematopoietic stem cell transplantation \(NG164\)](#)

Product type: Guidance

Programme: NICE guideline

Published date: 1 April 2020

13. [COVID-19 rapid guideline: delivery of radiotherapy \(NG162\)](#)

Product type: Guidance

Programme: NICE guideline

Published date: 28 March 2020

14. [COVID-19 rapid guideline: dialysis service delivery \(NG160\)](#)

Product type: Guidance

Programme: NICE guideline

Published date: 20 March 2020

15. [COVID-19 rapid evidence summary: acute use of non-steroidal anti-inflammatory drugs \(NSAIDs\) for people with or at risk of COVID-19 \(ES23\)](#)

Product type: Advice

Programme: Evidence summary

Published date: 14 April 2020

16. [Lifelight First for monitoring vital signs \(MIB213\)](#)

Product type: Advice

Programme: Medtech innovation briefing

Published date: 8 April 2020

17. [myCOPD for self-management of chronic obstructive pulmonary disease \(MIB214\)](#)

Product type: Advice

Programme: Medtech innovation briefing

Published date: 1 April 2020

MA-OTH-ES-0008-1
04/ 2020